Navigation Links
Helix BioPharma Closes Private Placement
Date:9/8/2009

AURORA, Ontario, Sept. 8 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP"; OTCQX: "HXBPF") today announced that it has closed its previously announced private placement of 6,625,000 units at $2.05 per unit.

Each unit consists of one common share and one common share purchase warrant, with each common share purchase warrant entitling the holder to purchase, subject to adjustment, one common share of the Company at a price of $2.87 for up to three years after the closing date of the private placement. Net proceeds after expenses are expected to be approximately $11.7 million and will be used for working capital, primarily to support the Company's expanding clinical trial initiatives.

The securities offered will not be and have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state of the United States, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha- 2b. Helix is listed on the TSX and FSE under the symbol "HBP" and the OTCQX International Market under the symbol "HXBPF".

    For further information contact:

    Investor & Media Relations
    Robert Flamm, Ph.D.
    Russo Partners LLC
    Tel:  (212) 845-4226
    Email: robert.flamm@russopartnersllc.com

    Ian Stone
    Russo Partners LLC
    Tel:  (619) 814-3510
   
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Helix BioPharma Announces $13.5 Million Private Placement
2. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
3. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
4. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
5. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
6. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
7. Helix BioPharma to Present at the BioFinance 2009 Conference
8. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
9. Helix BioPharma Announces Q2 2009 Financial Results
10. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
11. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2014)... the University of Illinois at Urbana-Champaign have demonstrated ... (pBNAs) can be used like traditional photographic film ... smaller than the wavelength of light (for example, ... A standard optical microscope acts as a "nanocamera" ... "Unlike conventional photographic film, the effect (writing and ...
(Date:7/18/2014)... 18, 2014 Emerging Nuclear Power Countries ... 2030 , Summary , The latest report from GlobalData, ... and Development Analysis to 2030 covers the emerging nuclear ... provides comprehensive information on key market players and their ... in various countries across the world has also been ...
(Date:7/17/2014)... WASHINGTON , July 17, 2014  Vanda Pharmaceuticals ... company focused on the development and commercialization of products ... announced it will release results for the second quarter ... market opens. The Company will host ... August 7, 2014, during which Vanda management will discuss ...
(Date:7/17/2014)... major road blocks to the design and development of ... Researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab) ... meaning a theoretical model free of adjustable or ... carriers" in semiconductors. Hot carriers are electrical charge carriers ... than charge carriers at thermal equilibrium. , "Hot carrier ...
Breaking Biology Technology:'Nanocamera' takes pictures at distances smaller than light's own wavelength 2Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 2Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 3Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014 2First ab initio method for characterizing hot carriers 2First ab initio method for characterizing hot carriers 3
... Aureus Pharma, a leading provider of,knowledge management ... release today of the new software solution ... evaluate target, cell and,drug profiles using bio-assays ... Pharma,s AurSCOPE Target Knowledge databases. AurPROFILER has ...
... Inc., the,operating company of WuXi PharmaTech (NYSE: ... of Garry Takle, Ph.D. as Vice President of ... Testing Services for its,Philadelphia facility., (Logo: ... with the company for nine years in roles ...
... HILL, N.C., Aug. 15 The U.S. ... into multiple market,segments. In this challenging marketplace, ... complex organizational and,decision-making structures to effectively represent ... being influenced by medical professionals,focused on efficacy ...
Cached Biology Technology:Aureus Pharma Releases AurPROFILER(R) - a New and Powerful Pharmacology Profiling Solution 2WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility 2U.S. Hospital Sales Opportunities Maximized Through Functional Optimization 2
(Date:7/21/2014)... developed a pioneering new way using samples of ... of drugs on the heart without using human or ... Dr Helen Maddock an expert in cardiovascular physiology ... and Exercise Sciences and could lead to the ... the quality of their treatments improved. , Adverse effects ...
(Date:7/21/2014)... Boston, MA Scientists at Brigham and Women,s Hospital ... generate fully functional human platelets in vitro. The work ... blood transfusion needs worldwide. , The study is published ... "The ability to generate an alternative source of functional ... paradigm shift in how we collect platelets that may ...
(Date:7/21/2014)... July 21, 2014 Research and Markets ( ... "Next Generation Biometric Market by Technology, Function, ... 2014 - 2020" report to their offering. ... is the verification of humans by their characteristics ... vein, and DNA. DNA and vein recognition are ...
Breaking Biology News(10 mins):New technique uses 'simulated' human heart to screen drugs 2Scientists successfully generate human platelets using next-generation bioreactor 2Global Next Generation Biometric Market by Technology, Function, Application & by Geography - Forecasts & Analysis to 2020 2Global Next Generation Biometric Market by Technology, Function, Application & by Geography - Forecasts & Analysis to 2020 3
... reef, the Scken reef in the Koster Fjord, is ... the University of Gothenburg have started a restoration project ... being removed and placed on the Scken reef. ... In Sweden, only one reef-building coral species exists, a ...
... prone to extinction than others? A new study of marine ... million years of fossil data for marine invertebrates reveals that ... hit even when populations are large, the authors report. ... surface. But because monitoring data are harder to collect at ...
... -- Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian ... Food and Drug Administration (FDA) has granted Meridian,s ... (pre-IND) meeting to discuss its plan to commence ... various cancer indications. The meeting is scheduled for ...
Cached Biology News:Sweden's only coral reef at risk of dying 2Sweden's only coral reef at risk of dying 3Fossil study helps pinpoint extinction risks for ocean animals 2FDA Grants Meridian Laboratories Pre-Ind Meeting for Captisol-Enabled Docetaxel in the Treatment of Cancer 2
... omental preadipocytes are isolated ... healthy donors. There is ... cells. Please inquire for ... also available. Academic discounts ...
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
Biology Products: